On November 3, 2021 EpiVax Therapeutics, Inc. ("EVT"), an emerging biotechnology company, reported that an abstract highlighting its Ancer platform will be presented at the upcoming Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 36th Annual Meeting from November 12-14, 2021 in Washington, DC (Press release, EpiVax, NOV 3, 2021, View Source [SID1234594283]). Details on the poster that will be presented as part of the regular submissions are below.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Title: Stealthier Mutanomes are Induced After Nivolumab Immunotherapy
Authors: Richard et. al
Poster #: 313
Presentation Date/Time: November 12, 2021, 7:00 am – 8:30 pm ET

The EpiVax Therapeutics Ancer platform will optimize precision immunotherapies development

"We are excited to share new research featuring the use of Ancer in novel biomarker identification. These new findings will optimize precision immunotherapies development at EpiVax Therapeutics," said Michael Princiotta, PhD, EpiVax Therapeutics CSO.